JPMorgan raised the firm’s price target on Doximity (DOCS) to $48 from $30 and keeps a Neutral rating on the shares. The firm updated estimates following Doximity’s fiscal Q2 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity initiated with a Neutral at Goldman Sachs
- American upgraded, Regeneron initiated: Wall Street’s top analyst calls
- Doximity price target raised to $49 from $35 at Truist
- Doximity upgraded to Equal Weight from Underweight at Morgan Stanley
- Starbucks, Spotify downgraded: Wall Street’s top analyst calls